1
|
Lazzerini PE, Bertolozzi I, Cartocci A, Ginjupalli VKM, Teneggi PA, Pica D, Merico G, Bogazzi I, Salvini V, Accioli R, Salvadori F, Marzotti T, Cevenini G, Capecchi M, Cantara S, Cantore A, Infantino M, Bisogno S, Finizola F, D'ascenzi F, Laghi‐Pasini F, Acampa M, Capecchi PL, Boutjdir M. Advanced Atrioventricular Block in Athletes: Prevalence and Role of Anti-Ro/Sjögren Syndrome-Related Antigen A Antibodies. J Am Heart Assoc 2024; 13:e034893. [PMID: 38879447 PMCID: PMC11255775 DOI: 10.1161/jaha.124.034893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Accepted: 04/15/2024] [Indexed: 06/19/2024]
Abstract
BACKGROUND Advanced atrioventricular block (AVB), that is, higher than second-degree Mobitz-1, is an abnormal finding in athletes. Despite intensive investigation, in several cases the pathogenesis remains unknown, but frequently pacemaker implantation is still indicated. Increasing evidence points to circulating anti-Ro/Sjögren syndrome-related antigen A (SSA) antibodies cross-reacting with L-type calcium channel and inhibiting the related current as an epidemiologically relevant and potentially reversible cause of isolated AVB in adults. The aim of the study was to determine the prevalence of anti-Ro/SSA-associated advanced AVBs in a large sample of young athletes. METHODS AND RESULTS A total of 2536 consecutive athletes aged <40 years without a history of cardiac diseases/interventions were enrolled in a cross-sectional study. Resting and exercise electrocardiography was performed, and those presenting any AVB were further evaluated by 24-hour Holter ECG. Athletes with second-degree AVBs and their mothers underwent anti-Ro/SSA testing. Moreover, purified immunoglobulin G from subjects with anti-Ro/SSA-positive and anti-Ro/SSA-negative advanced AVB were tested on L-type calcium current and L-type-calcium channel expression using tSA201 cells. The global prevalence of advanced AVB in the overall sample was ≈0.1%, but the risk considerably increased (2%) when intensely trained postpubertal male subjects were selectively considered. While none of the athletes with advanced AVB showed heart abnormalities, in 100% of cases anti-Ro/SSA antibodies were detected. Ex vivo experiments showed that immunoglobulin G from anti-Ro/SSA-positive but not -negative subjects with advanced AVB acutely inhibit L-type calcium current and chronically downregulate L-type-calcium channel expression. CONCLUSIONS Our study provides evidence that advanced AVB occurs in young athletes, in most cases associated with anti-Ro/SSA antibodies blocking L-type calcium channels. These findings may open new avenues for immunomodulating therapies to reduce the risk of life-threatening events in athletes, avoiding or delaying pacemaker implantation.
Collapse
Affiliation(s)
- Pietro Enea Lazzerini
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Iacopo Bertolozzi
- Cardiology Intensive Therapy UnitDepartment of Internal MedicineNuovo Ospedale San Giovanni di DioFlorenceItaly
- Former Cardiology Intensive Therapy Unit, Department of Internal MedicineHospital of CarraraCarraraItaly
| | | | | | | | - Davide Pica
- Center for Sports Medicine of CarraraASL Nord‐Ovest ToscanaMassa‐CarraraItaly
| | - Giovanni Merico
- Center for Sports Medicine of CarraraASL Nord‐Ovest ToscanaMassa‐CarraraItaly
| | - Irene Bogazzi
- Emergency DepartmentNuovo Ospedale ApuanoASL Nord‐Ovest ToscanaMassa‐CarraraItaly
| | - Viola Salvini
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Riccardo Accioli
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Fabio Salvadori
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Tommaso Marzotti
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | | | - Matteo Capecchi
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Silvia Cantara
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
- Laboratory of Clinical and Translational ResearchUniversity Hospital of SienaSienaItaly
| | - Anna Cantore
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Maria Infantino
- Immunology and Allergology Laboratory Unit S. Giovanni di Dio HospitalFlorenceItaly
| | - Stefania Bisogno
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Francesco Finizola
- Internal Medicine DepartmentSant’Antonio Abate Hospital of FivizzanoASL Nord‐Ovest ToscanaMassa‐CarraraItaly
| | - Flavio D'ascenzi
- Department of Medical BiotechnologiesSports Cardiology and Rehabilitation UnitUniversity of SienaSienaItaly
| | - Franco Laghi‐Pasini
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | | | - Pier Leopoldo Capecchi
- Department of Medical SciencesSurgery and Neurosciences, Division of Internal Medicine and Geriatrics, Electroimmunology UnitUniversity of SienaSienaItaly
| | - Mohamed Boutjdir
- Department of Medical BiotechnologiesUniversity of SienaSienaItaly
- New York University Grossman School of MedicineNew YorkNYUSA
| |
Collapse
|
2
|
Li T, Marashly Q, Kim JA, Li N, Chelu MG. Cardiac conduction diseases: understanding the molecular mechanisms to uncover targets for future treatments. Expert Opin Ther Targets 2024; 28:385-400. [PMID: 38700451 DOI: 10.1080/14728222.2024.2351501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Accepted: 05/01/2024] [Indexed: 05/05/2024]
Abstract
INTRODUCTION The cardiac conduction system (CCS) is crucial for maintaining adequate cardiac frequency at rest and modulation during exercise. Furthermore, the atrioventricular node and His-Purkinje system are essential for maintaining atrioventricular and interventricular synchrony and consequently maintaining an adequate cardiac output. AREAS COVERED In this review article, we examine the anatomy, physiology, and pathophysiology of the CCS. We then discuss in detail the most common genetic mutations and the molecular mechanisms of cardiac conduction disease (CCD) and provide our perspectives on future research and therapeutic opportunities in this field. EXPERT OPINION Significant advancement has been made in understanding the molecular mechanisms of CCD, including the recognition of the heterogeneous signaling at the subcellular levels of sinoatrial node, the involvement of inflammatory and autoimmune mechanisms, and the potential impact of epigenetic regulations on CCD. However, the current treatment of CCD manifested as bradycardia still relies primarily on cardiovascular implantable electronic devices (CIEDs). On the other hand, an If specific inhibitor was developed to treat inappropriate sinus tachycardia and sinus tachycardia in heart failure patients with reduced ejection fraction. More work is needed to translate current knowledge into pharmacologic or genetic interventions for the management of CCDs.
Collapse
Affiliation(s)
- Tingting Li
- Department of Medicine (Section of Cardiovascular Research), Baylor College of Medicine, Houston, TX, USA
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA
| | - Qussay Marashly
- Department of Cardiology, Montefiore Medical Center, New York, NY, USA
| | - Jitae A Kim
- Division of CardiovasculMedicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA
| | - Na Li
- Department of Medicine (Section of Cardiovascular Research), Baylor College of Medicine, Houston, TX, USA
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA
| | - Mihail G Chelu
- Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA
- Department of Medicine (Division of Cardiology), Baylor College of Medicine, Houston, TX, USA
- Division of Cardiology, Baylor St. Luke's Medical Center, Houston, TX, USA
- Division of Cardiology, Texas Heart Institute, Houston, TX, USA
| |
Collapse
|
3
|
Zaveri S, Srivastava U, Qu YS, Chahine M, Boutjdir M. Pathophysiology of Ca v1.3 L-type calcium channels in the heart. Front Physiol 2023; 14:1144069. [PMID: 37025382 PMCID: PMC10070707 DOI: 10.3389/fphys.2023.1144069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2023] [Accepted: 03/07/2023] [Indexed: 04/08/2023] Open
Abstract
Ca2+ plays a crucial role in excitation-contraction coupling in cardiac myocytes. Dysfunctional Ca2+ regulation alters the force of contraction and causes cardiac arrhythmias. Ca2+ entry into cardiomyocytes is mediated mainly through L-type Ca2+ channels, leading to the subsequent Ca2+ release from the sarcoplasmic reticulum. L-type Ca2+ channels are composed of the conventional Cav1.2, ubiquitously expressed in all heart chambers, and the developmentally regulated Cav1.3, exclusively expressed in the atria, sinoatrial node, and atrioventricular node in the adult heart. As such, Cav1.3 is implicated in the pathogenesis of sinoatrial and atrioventricular node dysfunction as well as atrial fibrillation. More recently, Cav1.3 de novo expression was suggested in heart failure. Here, we review the functional role, expression levels, and regulation of Cav1.3 in the heart, including in the context of cardiac diseases. We believe that the elucidation of the functional and molecular pathways regulating Cav1.3 in the heart will assist in developing novel targeted therapeutic interventions for the aforementioned arrhythmias.
Collapse
Affiliation(s)
- Sahil Zaveri
- Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, NY, United States
- Department of Medicine, Cell Biology and Pharmacology, State University of New York Downstate Health Sciences University, Brooklyn, New York, NY, United States
| | - Ujala Srivastava
- Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, NY, United States
| | - Yongxia Sarah Qu
- Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, NY, United States
- Department of Medicine, Cell Biology and Pharmacology, State University of New York Downstate Health Sciences University, Brooklyn, New York, NY, United States
- Department of Cardiology, New York Presbyterian Brooklyn Methodist Hospital, New York, NY, United States
| | - Mohamed Chahine
- CERVO Brain Research Center, Institut Universitaire en Santé Mentale de Québec, Québec, QC, Canada
- Department of Medicine, Faculté de Médecine, Université Laval, Quebec, QC, Canada
| | - Mohamed Boutjdir
- Cardiovascular Research Program, VA New York Harbor Healthcare System, New York, NY, United States
- Department of Medicine, Cell Biology and Pharmacology, State University of New York Downstate Health Sciences University, Brooklyn, New York, NY, United States
- Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, United States
- *Correspondence: Mohamed Boutjdir,
| |
Collapse
|
4
|
Meisgen S, Hedlund M, Ambrosi A, Folkersen L, Ottosson V, Forsberg D, Thorlacius GE, Biavati L, Strandberg L, Mofors J, Ramskold D, Ruhrmann S, Meneghel L, Nyberg W, Espinosa A, Hamilton RM, Franco-Cereceda A, Hamsten A, Olsson T, Greene L, Eriksson P, Gemzell-Danielsson K, Salomonsson S, Kuchroo VK, Herlenius E, Kockum I, Sonesson SE, Wahren-Herlenius M. Auxilin is a novel susceptibility gene for congenital heart block which directly impacts fetal heart function. Ann Rheum Dis 2022; 81:1151-1161. [PMID: 35470161 PMCID: PMC9279836 DOI: 10.1136/annrheumdis-2021-221714] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 04/11/2022] [Indexed: 11/03/2022]
Abstract
OBJECTIVE Neonatal lupus erythematosus (NLE) may develop after transplacental transfer of maternal autoantibodies with cardiac manifestations (congenital heart block, CHB) including atrioventricular block, atrial and ventricular arrhythmias, and cardiomyopathies. The association with anti-Ro/SSA antibodies is well established, but a recurrence rate of only 12%-16% despite persisting maternal autoantibodies suggests that additional factors are required for CHB development. Here, we identify fetal genetic variants conferring risk of CHB and elucidate their effects on cardiac function. METHODS A genome-wide association study was performed in families with at least one case of CHB. Gene expression was analysed by microarrays, RNA sequencing and PCR and protein expression by western blot, immunohistochemistry, immunofluorescence and flow cytometry. Calcium regulation and connectivity were analysed in primary cardiomyocytes and cells induced from pleuripotent stem cells. Fetal heart performance was analysed by Doppler/echocardiography. RESULTS We identified DNAJC6 as a novel fetal susceptibility gene, with decreased cardiac expression of DNAJC6 associated with the disease risk genotype. We further demonstrate that fetal cardiomyocytes deficient in auxilin, the protein encoded by DNAJC6, have abnormal connectivity and Ca2+ homoeostasis in culture, as well as decreased cell surface expression of the Cav1.3 calcium channel. Doppler echocardiography of auxilin-deficient fetal mice revealed cardiac NLE abnormalities in utero, including abnormal heart rhythm with atrial and ventricular ectopias, as well as a prolonged atrioventricular time intervals. CONCLUSIONS Our study identifies auxilin as the first genetic susceptibility factor in NLE modulating cardiac function, opening new avenues for the development of screening and therapeutic strategies in CHB.
Collapse
Affiliation(s)
- Sabrina Meisgen
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Malin Hedlund
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Aurelie Ambrosi
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Lasse Folkersen
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.,Technical University of Denmark, Lyngby, Denmark
| | - Vijole Ottosson
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - David Forsberg
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
| | - Gudny Ella Thorlacius
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Luca Biavati
- Department of Physiology and Experimental Medicine, Hospital for Sick Children, Washington, DC, USA
| | - Linn Strandberg
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Johannes Mofors
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Daniel Ramskold
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Sabrina Ruhrmann
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Lauro Meneghel
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - William Nyberg
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Alexander Espinosa
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | | | | | - Anders Hamsten
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Tomas Olsson
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Lois Greene
- National Institutes of Health, Bethesda, Maryland, USA
| | - Per Eriksson
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | | | - Stina Salomonsson
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Vijay K Kuchroo
- Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts, USA
| | - Eric Herlenius
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
| | - Ingrid Kockum
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Sven-Erik Sonesson
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
| | - Marie Wahren-Herlenius
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden .,Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| |
Collapse
|
5
|
Ambrosi A, Thorlacius GE, Sonesson SE, Wahren-Herlenius M. Interferons and innate immune activation in autoimmune congenital heart block. Scand J Immunol 2021; 93:e12995. [PMID: 33188653 DOI: 10.1111/sji.12995] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Revised: 10/26/2020] [Accepted: 11/06/2020] [Indexed: 12/12/2022]
Abstract
Autoimmune congenital heart block (CHB) may develop in foetuses of women carrying anti-Ro/SSA and La/SSB autoantibodies and is characterized by disruption of signal conduction at the atrioventricular (AV) node, resulting in partial or complete AV block. If not fatal in utero, complete CHB typically requires lifelong cardiac pacing. No treatment has so far been unequivocally demonstrated to prevent or treat autoimmune CHB, and the relatively low incidence (1%-5%) and recurrence (12%-16%) rates of second/third-degree AV block add to the complexity of managing pregnancies in women with anti-Ro/La antibodies. Altogether, a better understanding of events leading to development of autoimmune CHB is needed to improve surveillance and treatment strategies. In the past decade, studies have started to look beyond the role of maternal autoantibodies in disease pathogenesis to assess other contributing factors such as foetal genetics and, more recently, immune responses in foetuses and neonates of anti-Ro/La antibody-positive women. In this review, we provide an update on the epidemiology, clinical presentation and current treatment approaches of autoimmune CHB, summarize the previously proposed pathogenic mechanisms implicating maternal autoantibodies, and discuss the recent findings of type I interferon (IFN) and innate immune activation in foetuses with autoimmune CHB and in neonates of anti-Ro/La antibody-positive mothers, and how these may contribute to autoimmune CHB pathogenesis.
Collapse
Affiliation(s)
- Aurelie Ambrosi
- Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Gudny Ella Thorlacius
- Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - Sven-Erik Sonesson
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
| | - Marie Wahren-Herlenius
- Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.,Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| |
Collapse
|
6
|
Mesirca P, Fedorov VV, Hund TJ, Torrente AG, Bidaud I, Mohler PJ, Mangoni ME. Pharmacologic Approach to Sinoatrial Node Dysfunction. Annu Rev Pharmacol Toxicol 2020; 61:757-778. [PMID: 33017571 DOI: 10.1146/annurev-pharmtox-031120-115815] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The spontaneous activity of the sinoatrial node initiates the heartbeat. Sino-atrial node dysfunction (SND) and sick sinoatrial (sick sinus) syndrome are caused by the heart's inability to generate a normal sinoatrial node action potential. In clinical practice, SND is generally considered an age-related pathology, secondary to degenerative fibrosis of the heart pacemaker tissue. However, other forms of SND exist, including idiopathic primary SND, which is genetic, and forms that are secondary to cardiovascular or systemic disease. The incidence of SND in the general population is expected to increase over the next half century, boosting the need to implant electronic pacemakers. During the last two decades, our knowledge of sino-atrial node physiology and of the pathophysiological mechanisms underlying SND has advanced considerably. This review summarizes the current knowledge about SND mechanisms and discusses the possibility of introducing new pharmacologic therapies for treating SND.
Collapse
Affiliation(s)
- Pietro Mesirca
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34096 Montpellier, France; .,LabEx Ion Channels Science and Therapeutics (ICST), 06560 Nice, France
| | - Vadim V Fedorov
- Frick Center for Heart Failure and Arrhythmia at the Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio 43210, USA.,Department of Physiology and Cell Biology, The Ohio State University College of Medicine, Wexner Medical Center, Columbus, Ohio 43210, USA
| | - Thomas J Hund
- Frick Center for Heart Failure and Arrhythmia at the Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio 43210, USA.,Department of Biomedical Engineering, The Ohio State University, Columbus, Ohio 43210, USA
| | - Angelo G Torrente
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34096 Montpellier, France; .,LabEx Ion Channels Science and Therapeutics (ICST), 06560 Nice, France
| | - Isabelle Bidaud
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34096 Montpellier, France; .,LabEx Ion Channels Science and Therapeutics (ICST), 06560 Nice, France
| | - Peter J Mohler
- Frick Center for Heart Failure and Arrhythmia at the Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio 43210, USA.,Department of Physiology and Cell Biology, The Ohio State University College of Medicine, Wexner Medical Center, Columbus, Ohio 43210, USA.,Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA
| | - Matteo E Mangoni
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 34096 Montpellier, France; .,LabEx Ion Channels Science and Therapeutics (ICST), 06560 Nice, France
| |
Collapse
|
7
|
Torrente AG, Mesirca P, Bidaud I, Mangoni ME. Channelopathies of voltage-gated L-type Cav1.3/α 1D and T-type Cav3.1/α 1G Ca 2+ channels in dysfunction of heart automaticity. Pflugers Arch 2020; 472:817-830. [PMID: 32601767 DOI: 10.1007/s00424-020-02421-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 06/12/2020] [Accepted: 06/19/2020] [Indexed: 10/24/2022]
Abstract
The heart automaticity is a fundamental physiological function in vertebrates. The cardiac impulse is generated in the sinus node by a specialized population of spontaneously active myocytes known as "pacemaker cells." Failure in generating or conducting spontaneous activity induces dysfunction in cardiac automaticity. Several families of ion channels are involved in the generation and regulation of the heart automaticity. Among those, voltage-gated L-type Cav1.3 (α1D) and T-type Cav3.1 (α1G) Ca2+ channels play important roles in the spontaneous activity of pacemaker cells. Ca2+ channel channelopathies specifically affecting cardiac automaticity are considered rare. Recent research on familial disease has identified mutations in the Cav1.3-encoding CACNA1D gene that underlie congenital sinus node dysfunction and deafness (OMIM # 614896). In addition, both Cav1.3 and Cav3.1 channels have been identified as pathophysiological targets of sinus node dysfunction and heart block, caused by congenital autoimmune disease of the cardiac conduction system. The discovery of channelopathies linked to Cav1.3 and Cav3.1 channels underscores the importance of Ca2+ channels in the generation and regulation of heart's automaticity.
Collapse
Affiliation(s)
- Angelo G Torrente
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 141, rue de la cardonille, 34094, Montpellier, France.,LabEx Ion Channels Science and Therapeutics (ICST), Montpellier, France
| | - Pietro Mesirca
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 141, rue de la cardonille, 34094, Montpellier, France.,LabEx Ion Channels Science and Therapeutics (ICST), Montpellier, France
| | - Isabelle Bidaud
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 141, rue de la cardonille, 34094, Montpellier, France.,LabEx Ion Channels Science and Therapeutics (ICST), Montpellier, France
| | - Matteo E Mangoni
- Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, 141, rue de la cardonille, 34094, Montpellier, France. .,LabEx Ion Channels Science and Therapeutics (ICST), Montpellier, France.
| |
Collapse
|
8
|
Novel re-expression of L-type calcium channel Ca v1.3 in left ventricles of failing human heart. Heart Rhythm 2020; 17:1193-1197. [PMID: 32113898 DOI: 10.1016/j.hrthm.2020.02.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Accepted: 02/19/2020] [Indexed: 11/17/2022]
|
9
|
Qu YS, Lazzerini PE, Capecchi PL, Laghi-Pasini F, El Sherif N, Boutjdir M. Autoimmune Calcium Channelopathies and Cardiac Electrical Abnormalities. Front Cardiovasc Med 2019; 6:54. [PMID: 31119135 PMCID: PMC6507622 DOI: 10.3389/fcvm.2019.00054] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 04/16/2019] [Indexed: 12/24/2022] Open
Abstract
Patients with autoimmune diseases are at increased risk for developing cardiovascular diseases, and abnormal electrocardiographic findings are common. Voltage-gated calcium channels play a major role in the cardiovascular system and regulate cardiac excitability and contractility. Particularly, by virtue of their localization and expression in the heart, calcium channels modulate pace making at the sinus node, conduction at the atrioventricular node and cardiac repolarization in the working myocardium. Consequently, emerging evidence suggests that calcium channels are targets to autoantibodies in autoimmune diseases. Autoimmune-associated cardiac calcium channelopathies have been recognized in both sinus node dysfunction atrioventricular block in patients positive for anti-Ro/La antibodies, and ventricular arrhythmias in patients with dilated cardiomyopathy. In this review, we discuss mechanisms of autoimmune-associated calcium channelopathies and their relationship with the development of cardiac electrical abnormalities.
Collapse
Affiliation(s)
- Yongxia Sarah Qu
- Department of Cardiology, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, United States.,VA New York Harbor Healthcare System and State University of New York Downstate Medical Center, Brooklyn, NY, United States
| | - Pietro Enea Lazzerini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Pier Leopoldo Capecchi
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Franco Laghi-Pasini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Nabil El Sherif
- VA New York Harbor Healthcare System and State University of New York Downstate Medical Center, Brooklyn, NY, United States
| | - Mohamed Boutjdir
- VA New York Harbor Healthcare System and State University of New York Downstate Medical Center, Brooklyn, NY, United States.,NYU School of Medicine, New York, NY, United States
| |
Collapse
|
10
|
Seidelmann SB, Smith E, Subrahmanyan L, Dykas D, Abou Ziki MD, Azari B, Hannah-Shmouni F, Jiang Y, Akar JG, Marieb M, Jacoby D, Bale AE, Lifton RP, Mani A. Application of Whole Exome Sequencing in the Clinical Diagnosis and Management of Inherited Cardiovascular Diseases in Adults. ACTA ACUST UNITED AC 2017; 10:CIRCGENETICS.116.001573. [PMID: 28087566 DOI: 10.1161/circgenetics.116.001573] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Accepted: 12/01/2016] [Indexed: 12/17/2022]
Abstract
BACKGROUND With the advent of high throughput sequencing, the identification of genetic causes of cardiovascular disease (CVD) has become an integral part of medical diagnosis and management and at the forefront of personalized medicine in this field. The use of whole exome sequencing for clinical diagnosis, risk stratification, and management of inherited CVD has not been previously evaluated. METHODS AND RESULTS We analyzed the results of whole exome sequencing in first 200 adult patients with inherited CVD, who underwent genetic testing at the Yale Program for Cardiovascular Genetics. Genetic diagnosis was reached and reported with a success rate of 26.5% (53 of 200 patients). This compares to 18% (36 of 200) that would have been diagnosed using commercially available genetic panels (P=0.04). Whole exome sequencing was particularly useful for clinical diagnosis in patients with aborted sudden cardiac death, in whom the primary insult for the presence of both depressed cardiac function and prolonged QT had remained unknown. The analysis of the remaining cases using genome annotation and disease segregation led to the discovery of novel candidate genes in another 14% of the cases. CONCLUSIONS Whole exome sequencing is an exceptionally valuable screening tool for its capability to establish the clinical diagnosis of inherited CVDs, particularly for poorly defined cases of sudden cardiac death. By presenting novel candidate genes and their potential disease associations, we also provide evidence for the use of this genetic tool for the identification of novel CVD genes. Creation and sharing of exome databases across centers of care should facilitate the discovery of unknown CVD genes.
Collapse
Affiliation(s)
- Sara B Seidelmann
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Emily Smith
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Lakshman Subrahmanyan
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Daniel Dykas
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Maen D Abou Ziki
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Bani Azari
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Fady Hannah-Shmouni
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Yuexin Jiang
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Joseph G Akar
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Mark Marieb
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Daniel Jacoby
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Allen E Bale
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Richard P Lifton
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.)
| | - Arya Mani
- From the Division of Cardiovascular Medicine (S.B.S., E.S., L.S., M.D.A.Z., B.A., J.G.A., M.M., D.J., A.M.), Yale Program for Cardiovascular Genetics (S.B.S., E.S., L.S., F.H.-S., A.M.), Department of Genetics, Yale School of Medicine, New Haven, CT (D.D., A.E.B., R.P.L., A.M.); Division of Cardiovascular Medicine, Department of Radiology (S.B.S.) and Division of Cardiac Imaging (S.B.S.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Key Laboratory of Clinical Trail Research in Cardiovascular Drugs, Ministry of Health Cardiovascular Institute, Fu Wai Hospital, CAMS and PUMC, Beijing, China (Y.J.).
| |
Collapse
|
11
|
Ca V1.3 L-type Ca 2+ channel contributes to the heartbeat by generating a dihydropyridine-sensitive persistent Na + current. Sci Rep 2017; 7:7869. [PMID: 28801600 PMCID: PMC5554211 DOI: 10.1038/s41598-017-08191-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Accepted: 07/07/2017] [Indexed: 11/22/2022] Open
Abstract
The spontaneous activity of sinoatrial node (SAN) pacemaker cells is generated by a functional interplay between the activity of ionic currents of the plasma membrane and intracellular Ca2+ dynamics. The molecular correlate of a dihydropyridine (DHP)-sensitive sustained inward Na+ current (Ist), a key player in SAN automaticity, is still unknown. Here we show that Ist and the L-type Ca2+ current (ICa,L) share CaV1.3 as a common molecular determinant. Patch-clamp recordings of mouse SAN cells showed that Ist is activated in the diastolic depolarization range, and displays Na+ permeability and minimal inactivation and sensitivity to ICa,L activators and blockers. Both CaV1.3-mediated ICa,L and Ist were abolished in CaV1.3-deficient (CaV1.3−/−) SAN cells but the CaV1.2-mediated ICa,L current component was preserved. In SAN cells isolated from mice expressing DHP-insensitive CaV1.2 channels (CaV1.2DHP−/−), Ist and CaV1.3-mediated ICa,L displayed overlapping sensitivity and concentration–response relationships to the DHP blocker nifedipine. Consistent with the hypothesis that CaV1.3 rather than CaV1.2 underlies Ist, a considerable fraction of ICa,L was resistant to nifedipine inhibition in CaV1.2DHP−/− SAN cells. These findings identify CaV1.3 channels as essential molecular components of the voltage-dependent, DHP-sensitive Ist Na+ current in the SAN.
Collapse
|
12
|
Lazzerini PE, Capecchi PL, Laghi-Pasini F, Boutjdir M. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias. Nat Rev Cardiol 2017; 14:521-535. [PMID: 28470179 DOI: 10.1038/nrcardio.2017.61] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cardiac arrhythmias confer a considerable burden of morbidity and mortality in industrialized countries. Although coronary artery disease and heart failure are the prevalent causes of cardiac arrest, in 5-15% of patients, structural abnormalities at autopsy are absent. In a proportion of these patients, mutations in genes encoding cardiac ion channels are documented (inherited channelopathies), but, to date, the molecular autopsy is negative in nearly 70% of patients. Emerging evidence indicates that autoimmunity is involved in the pathogenesis of cardiac arrhythmias. In particular, several arrhythmogenic autoantibodies targeting specific calcium, potassium, or sodium channels in the heart have been identified. Experimental and clinical studies demonstrate that these autoantibodies can promote conduction disturbances and life-threatening tachyarrhythmias by inducing substantial electrophysiological changes. In this Review, we propose the term 'autoimmune cardiac channelopathies' to define this novel pathogenic mechanism of cardiac arrhythmias, which could be more frequent and clinically relevant than previously appreciated. Indeed, pathogenic autoantibodies against ion channels are detectable not only in patients with manifest autoimmune disease, but also in apparently healthy individuals, which suggests a causal role in some cases of unexplained arrhythmias and cardiac arrest. Considering this possibility and performing specific testing in patients with 'idiopathic' rhythm disturbances could create novel treatment opportunities.
Collapse
Affiliation(s)
- Pietro Enea Lazzerini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Viale Bracci 16, Siena, 53100, Italy
| | - Pier Leopoldo Capecchi
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Viale Bracci 16, Siena, 53100, Italy
| | - Franco Laghi-Pasini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Viale Bracci 16, Siena, 53100, Italy
| | - Mohamed Boutjdir
- VA New York Harbor Healthcare System, 800 Poly Place, Brooklyn, New York 11209, USA.,SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, New York 11203, USA.,NYU School of Medicine, 550 1st Avenue, New York, New York 10016, USA
| |
Collapse
|
13
|
Hoxha A, Ruffatti A, Ambrosi A, Ottosson V, Hedlund M, Ottosson L, Anandapadamanaban M, Sunnerhagen M, Sonesson SE, Wahren-Herlenius M. Identification of discrete epitopes of Ro52p200 and association with fetal cardiac conduction system manifestations in a rodent model. Clin Exp Immunol 2016; 186:284-291. [PMID: 27548532 DOI: 10.1111/cei.12854] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Accepted: 08/08/2016] [Indexed: 11/30/2022] Open
Abstract
Congenital heart block (CHB) is a potentially lethal condition characterized by a third-degree atrioventricular block (AVB). Despite anti-Ro52 antibodies being detected in nearly 90% of mothers of affected children, CHB occurs in only 1-2% of anti-Ro/Sjögren's-syndrome-related antigen A (SSA) autoantibody-positive pregnancies. Maternal antibodies have been suggested to bind molecules crucial to fetal cardiac function; however, it remains unknown whether a single antibody profile associates with CHB or whether several specificities and cross-reactive targets exist. Here, we aimed to define further the reactivity profile of CHB-associated antibodies towards Ro52p200 (amino acid 200-239). We first analysed reactivity of a monoclonal anti-Ro52 antibody shown to induce AVB in rats (7.8C7) and of sera from anti-Ro52p200 antibody-positive mothers of children with CHB towards a panel of modified Ro52p200 peptides, and subsequently evaluated their potential to induce AVB in rats upon transfer during gestation. We observed that CHB maternal sera displayed a homogeneous reactivity profile targeting preferentially the C-terminal part of Ro52p200, in contrast to 7.8C7 that specifically bound the p200 N-terminal end. In particular, amino acid D233 appeared crucial to maternal antibody reactivity towards p200. Despite low to absent reactivity towards rat p200 and different binding profiles towards mutated rat peptides indicating recognition of different epitopes within Ro52p200, immunoglobulin (Ig)G purified from two mothers of children with CHB could induce AVB in rats. Our findings support the hypothesis that several fine antibody specificities and cross-targets may exist and contribute to CHB development in anti-Ro52 antibody-positive pregnancies.
Collapse
Affiliation(s)
- A Hoxha
- Department of Medicine, Rheumatology Unit, University of Padua, Padua, Italy.,Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - A Ruffatti
- Department of Medicine, Rheumatology Unit, University of Padua, Padua, Italy
| | - A Ambrosi
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - V Ottosson
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - M Hedlund
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | - L Ottosson
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| | | | - M Sunnerhagen
- Department of Medical Biophysics, Linköping University, Linköping, Sweden
| | - S-E Sonesson
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
| | - M Wahren-Herlenius
- Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
14
|
Fabris F, Yue Y, Qu Y, Chahine M, Sobie E, Lee P, Wieczorek R, Jiang XC, Capecchi PL, Laghi-Pasini F, Lazzerini PE, Boutjdir M. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea-pigs. J Physiol 2016; 594:6175-6187. [PMID: 27296897 DOI: 10.1113/jp272151] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 06/01/2016] [Indexed: 11/08/2022] Open
Abstract
KEY POINTS Channelopathies of autoimmune origin are novel and are associated with corrected QT (QTc) prolongation and complex ventricular arrhythmias. We have recently demonstrated that anti-SSA/Ro antibodies from patients with autoimmune diseases and with QTc prolongation on the ECG target the human ether-à-go-go-related gene (HERG) K+ channel by inhibiting the corresponding current, IKr , at the pore region. Immunization of guinea-pigs with a peptide (E-pore peptide) corresponding to the extracellular loop region connecting the S5 and S6 segments of the HERG channel induces high titres of antibodies that inhibit IKr , lengthen the action potential and cause QTc prolongation on the surface ECG. In addition, anti-SSA/Ro-positive sera from patients with connective tissue diseases showed high reactivity to the E-pore peptide. The translational impact is the development of a peptide-based approach for the diagnosis and treatment of autoimmune-associated long QT syndrome. ABSTRACT We recently demonstrated that anti-SSA/52 kDa Ro antibodies (Abs) from patients with autoimmune diseases and corrected QT (QTc) prolongation directly target and inhibit the human ether-à-go-go-related gene (HERG) K+ channel at the extracellular pore (E-pore) region, where homology with SSA/52 kDa Ro antigen was demonstrated. We tested the hypothesis that immunization of guinea-pigs with a peptide corresponding to the E-pore region (E-pore peptide) will generate pathogenic inhibitory Abs and cause QTc prolongation. Guinea-pigs were immunized with a 31-amino-acid peptide corresponding to the E-pore region of HERG. On days 10-62 after immunization, ECGs were recorded and blood was sampled for the detection of E-pore peptide Abs. Serum samples from patients with autoimmune diseases were evaluated for reactivity to E-pore peptide by enzyme-linked immunosorbent assay (ELISA), and histology was performed on hearts using Masson's Trichrome. Inhibition of the HERG channel was assessed by electrophysiology and by computational modelling of the human ventricular action potential. The ELISA results revealed the presence of high titres of E-pore peptide Abs and significant QTc prolongation after immunization. High reactivity to E-pore peptide was found using anti-SSA/Ro Ab-positive sera from patients with QTc prolongation. Histological data showed no evidence of fibrosis in immunized hearts. Simulations of simultaneous inhibition of repolarizing currents by anti-SSA/Ro Ab-positive sera showed the predominance of the HERG channel in controlling action potential duration and the QT interval. These results are the first to demonstrate that inhibitory Abs to the HERG E-pore region induce QTc prolongation in immunized guinea-pigs by targeting the HERG channel independently from fibrosis. The reactivity of anti-SSA/Ro Ab-positive sera from patients with connective tissue diseases with the E-pore peptide opens novel pharmacotherapeutic avenues in the diagnosis and management of autoimmune-associated QTc prolongation.
Collapse
Affiliation(s)
- Frank Fabris
- Cardiovascular Research Program, VA New York Harbor Healthcare System, Brooklyn, NY, USA.,Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA
| | - Yuankun Yue
- Cardiovascular Research Program, VA New York Harbor Healthcare System, Brooklyn, NY, USA
| | - Yongxia Qu
- Cardiovascular Research Program, VA New York Harbor Healthcare System, Brooklyn, NY, USA.,Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA
| | - Mohamed Chahine
- Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec, Laval University, Quebec City, QC, Canada
| | - Eric Sobie
- Department of Pharmacology & Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Peng Lee
- Pathology Department, VA New York Harbor Healthcare System, New York, NY, USA.,Department of Pathology, New York University School of Medicine, New York, NY, USA
| | - Rosemary Wieczorek
- Pathology Department, VA New York Harbor Healthcare System, New York, NY, USA
| | - Xian-Cheng Jiang
- Cardiovascular Research Program, VA New York Harbor Healthcare System, Brooklyn, NY, USA.,Department of Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY, USA
| | - Pier-Leopoldo Capecchi
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Franco Laghi-Pasini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Pietro-Enea Lazzerini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Mohamed Boutjdir
- Cardiovascular Research Program, VA New York Harbor Healthcare System, Brooklyn, NY, USA. .,Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, NY, USA. .,Department of Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY, USA. .,Department of Pharmacology, State University of New York Downstate Medical Center, Brooklyn, NY, USA. .,Department of Medicine, New York University School of Medicine, New York, NY, USA.
| |
Collapse
|
15
|
Boutjdir M, Lazzerini PE, Capecchi PL, Laghi-Pasini F, El-Sherif N. Potassium Channel Block and Novel Autoimmune-Associated Long QT Syndrome. Card Electrophysiol Clin 2016; 8:373-84. [PMID: 27261828 DOI: 10.1016/j.ccep.2016.02.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
This article reviews advances in the pathogenesis of anti-SSA/Ro antibody-induced corrected QT (QTc) prolongation in patients with autoimmune diseases; particularly connective tissue disease (CTD). Evidence shows that anti-SSA/Ro antibody-positive patients with CTD show QTc prolongation and complex ventricular arrhythmias. Molecular and functional data provide evidence that the human ether-a-go-go-related gene potassium channel conducting the rapidly activating delayed rectifier potassium current is directly inhibited by anti-SSA/Ro antibodies, resulting in action potential duration prolongation leading to QT interval lengthening. Routine electrocardiogram screening in anti-SSA/Ro antibody-positive patients and counseling for patients with other QTc prolonging risk factors is recommended.
Collapse
Affiliation(s)
- Mohamed Boutjdir
- Research and Development Service, VA New York Harbor Healthcare System, 800 Poly Place, Brooklyn, NY 11209, USA; Departments of Medicine, Cell Biology and Pharmacology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA; Department of Medicine, NYU School of Medicine, 550, 1st Avenue, New York, NY 10016, USA
| | - Pietro Enea Lazzerini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Policlinico "Le Scotte", Viale Bracci, Siena 53100, Italy
| | - Pier Leopoldo Capecchi
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Policlinico "Le Scotte", Viale Bracci, Siena 53100, Italy
| | - Franco Laghi-Pasini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Policlinico "Le Scotte", Viale Bracci, Siena 53100, Italy
| | - Nabil El-Sherif
- Research and Development Service, VA New York Harbor Healthcare System, 800 Poly Place, Brooklyn, NY 11209, USA; Departments of Medicine, Cell Biology and Pharmacology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA.
| |
Collapse
|
16
|
G protein-gated IKACh channels as therapeutic targets for treatment of sick sinus syndrome and heart block. Proc Natl Acad Sci U S A 2016; 113:E932-41. [PMID: 26831068 DOI: 10.1073/pnas.1517181113] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Dysfunction of pacemaker activity in the sinoatrial node (SAN) underlies "sick sinus" syndrome (SSS), a common clinical condition characterized by abnormally low heart rate (bradycardia). If untreated, SSS carries potentially life-threatening symptoms, such as syncope and end-stage organ hypoperfusion. The only currently available therapy for SSS consists of electronic pacemaker implantation. Mice lacking L-type Cav1.3 Ca(2+) channels (Cav1.3(-/-)) recapitulate several symptoms of SSS in humans, including bradycardia and atrioventricular (AV) dysfunction (heart block). Here, we tested whether genetic ablation or pharmacological inhibition of the muscarinic-gated K(+) channel (IKACh) could rescue SSS and heart block in Cav1.3(-/-) mice. We found that genetic inactivation of IKACh abolished SSS symptoms in Cav1.3(-/-) mice without reducing the relative degree of heart rate regulation. Rescuing of SAN and AV dysfunction could be obtained also by pharmacological inhibition of IKACh either in Cav1.3(-/-) mice or following selective inhibition of Cav1.3-mediated L-type Ca(2+) (ICa,L) current in vivo. Ablation of IKACh prevented dysfunction of SAN pacemaker activity by allowing net inward current to flow during the diastolic depolarization phase under cholinergic activation. Our data suggest that patients affected by SSS and heart block may benefit from IKACh suppression achieved by gene therapy or selective pharmacological inhibition.
Collapse
|
17
|
Torrente AG, Mesirca P, Neco P, Rizzetto R, Dubel S, Barrere C, Sinegger-Brauns M, Striessnig J, Richard S, Nargeot J, Gomez AM, Mangoni ME. L-type Cav1.3 channels regulate ryanodine receptor-dependent Ca2+ release during sino-atrial node pacemaker activity. Cardiovasc Res 2016; 109:451-61. [PMID: 26786159 DOI: 10.1093/cvr/cvw006] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 01/07/2016] [Indexed: 11/13/2022] Open
Abstract
AIMS Sino-atrial node (SAN) automaticity is an essential mechanism of heart rate generation that is still not completely understood. Recent studies highlighted the importance of intracellular Ca(2+) ([Ca(2+)]i) dynamics during SAN pacemaker activity. Nevertheless, the functional role of voltage-dependent L-type Ca(2+) channels in controlling SAN [Ca(2+)]i release is largely unexplored. Since Cav1.3 is the predominant L-type Ca(2+) channel isoform in SAN cells, we studied [Ca(2+)]i dynamics in isolated cells and ex vivo SAN preparations explanted from wild-type (WT) and Cav1.3 knockout (KO) mice (Cav1.3(-/-)). METHODS AND RESULTS We found that Cav1.3 deficiency strongly impaired [Ca(2+)]i dynamics, reducing the frequency of local [Ca(2+)]i release events and preventing their synchronization. This impairment inhibited the generation of Ca(2+) transients and delayed spontaneous activity. We also used action potentials recorded in WT SAN cells as voltage-clamp commands for Cav1.3(-/-) cells. Although these experiments showed abolished Ca(2+) entry through L-type Ca(2+) channels in the diastolic depolarization range of KO SAN cells, their sarcoplasmic reticulum Ca(2+) load remained normal. β-Adrenergic stimulation enhanced pacemaking of both genotypes, though, Cav1.3(-/-) SAN cells remained slower than WT. Conversely, we rescued pacemaker activity in Cav1.3(-/-) SAN cells and intact tissues through caffeine-mediated stimulation of Ca(2+)-induced Ca(2+) release. CONCLUSIONS Cav1.3 channels play a critical role in the regulation of [Ca(2+)]i dynamics, providing an unanticipated mechanism for triggering local [Ca(2+)]i releases and thereby controlling pacemaker activity. Our study also provides an additional pathophysiological mechanism for congenital SAN dysfunction and heart block linked to Cav1.3 loss of function in humans.
Collapse
Affiliation(s)
- Angelo Giovanni Torrente
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| | - Pietro Mesirca
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| | - Patricia Neco
- UMR-S 1180, Inserm, Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France Department of Pharmacology and Toxicology, Institute of Pharmacy
| | - Riccardo Rizzetto
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| | - Stefan Dubel
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| | - Christian Barrere
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| | - Martina Sinegger-Brauns
- Department of Pharmacology and Toxicology, Institute of Pharmacy Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria
| | - Joerg Striessnig
- Department of Pharmacology and Toxicology, Institute of Pharmacy Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria
| | - Sylvain Richard
- INSERM, U1046, Montpellier, France CNRS UMR 9214, PhyMedExp, University of Montpellier, France
| | - Joël Nargeot
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| | - Ana Maria Gomez
- UMR-S 1180, Inserm, Univ. Paris-Sud, Université Paris-Saclay, Châtenay-Malabry, France Department of Pharmacology and Toxicology, Institute of Pharmacy
| | - Matteo Elia Mangoni
- Département de Physiologie, CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Montpellier F-34000, France INSERM, U1191, Montpellier F-34000, France Université de Montpellier, UMR-5203, Montpellier F-34000, France
| |
Collapse
|
18
|
Abadir S, Fournier A, Vobecky SJ, Rohlicek CV, Romeo P, Khairy P. Left Atrial Inexcitability in Children With Congenital Lupus-Induced Complete Atrioventricular Block. J Am Heart Assoc 2015; 4:JAHA.115.002676. [PMID: 26675254 PMCID: PMC4845288 DOI: 10.1161/jaha.115.002676] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Background Congenital atrioventricular block is a well‐established immunologic complication of maternal systemic lupus erythematosus. We sought to further characterize the electrophysiological manifestations of maternal systemic lupus erythematosus on neonatal atria. Methods and Results Cases of isolated congenital atrioventricular block treated at our center over the past 41 years were identified. Data were extracted from clinical charts, pacemaker interrogations, ECGs, echocardiograms, and histopathological reports, when available. Of 31 patients with isolated congenital atrioventricular block, 18 were negative for maternal antibodies and had normal epicardial atrial sensing and pacing thresholds. In contrast, 12 of 13 patients with positive maternal antibodies had epicardial pacemakers, 5 (42%) of whom had left atrial (LA) inexcitability and/or atrial conduction delay. In 3 patients, the LA could not be captured despite high‐output pacing. The fourth patient had acutely successful LA appendage and left ventricular lead placement. At early follow‐up, an increased delay between the surface P‐wave and intracardiac atrial depolarization was observed, indicative of atrial conduction delay. The fifth patient exhibited LA lead dysfunction, with atrial under‐sensing and an increased capture threshold, 2 weeks after implantation. Biopsies of LA appendages performed in 2 patients showed no evidence of atrial fibrosis or loss of atrial myocytes. Conclusions Herein, we report previously undescribed yet prevalent electrophysiological ramifications of maternal systemic lupus erythematosus, which extend beyond congenital atrioventricular block to encompass alterations in LA conduction, including LA inexcitability. These manifestations can complicate epicardial pacemaker implantation in newborns. In the absence of histological evidence of extensive atrial fibrosis, immune‐mediated functional impairment of electrical activity is suspected.
Collapse
Affiliation(s)
- Sylvia Abadir
- Divisions of Cardiology and Cardiac Surgery, CHU mère-enfant Sainte-Justine, Université de Montréal, Quebec, Canada (S.A., A.F., S.J.V., P.K.) Department of Cardiology, Montreal Children's Hospital, McGill University, Montreal, Quebec, Canada (S.A., C.V.R.)
| | - Anne Fournier
- Divisions of Cardiology and Cardiac Surgery, CHU mère-enfant Sainte-Justine, Université de Montréal, Quebec, Canada (S.A., A.F., S.J.V., P.K.)
| | - Suzanne J Vobecky
- Divisions of Cardiology and Cardiac Surgery, CHU mère-enfant Sainte-Justine, Université de Montréal, Quebec, Canada (S.A., A.F., S.J.V., P.K.)
| | - Charles V Rohlicek
- Department of Cardiology, Montreal Children's Hospital, McGill University, Montreal, Quebec, Canada (S.A., C.V.R.)
| | - Philippe Romeo
- Department of Medicine and Pathology, Montreal Heart Institute, Université de Montréal, Québec, Canada (P.R., P.K.)
| | - Paul Khairy
- Divisions of Cardiology and Cardiac Surgery, CHU mère-enfant Sainte-Justine, Université de Montréal, Quebec, Canada (S.A., A.F., S.J.V., P.K.) Department of Medicine and Pathology, Montreal Heart Institute, Université de Montréal, Québec, Canada (P.R., P.K.)
| |
Collapse
|
19
|
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT Syndrome: An Emerging Role for Inflammation and Immunity. Front Cardiovasc Med 2015; 2:26. [PMID: 26798623 PMCID: PMC4712633 DOI: 10.3389/fcvm.2015.00026] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Accepted: 05/08/2015] [Indexed: 01/07/2023] Open
Abstract
The long QT syndrome (LQTS), classified as congenital or acquired, is a multi-factorial disorder of myocardial repolarization predisposing to life-threatening ventricular arrhythmias, particularly torsades de pointes. In the latest years, inflammation and immunity have been increasingly recognized as novel factors crucially involved in modulating ventricular repolarization. In the present paper, we critically review the available information on this topic, also analyzing putative mechanisms and potential interplays with the other etiologic factors, either acquired or inherited. Accumulating data indicate inflammatory activation as a potential cause of acquired LQTS. The putative underlying mechanisms are complex but essentially cytokine-mediated, including both direct actions on cardiomyocyte ion channels expression and function, and indirect effects resulting from an increased central nervous system sympathetic drive on the heart. Autoimmunity represents another recently arising cause of acquired LQTS. Indeed, increasing evidence demonstrates that autoantibodies may affect myocardial electric properties by directly cross-reacting with the cardiomyocyte and interfering with specific ion currents as a result of molecular mimicry mechanisms. Intriguingly, recent data suggest that inflammation and immunity may be also involved in modulating the clinical expression of congenital forms of LQTS, possibly triggering or enhancing electrical instability in patients who already are genetically predisposed to arrhythmias. In this view, targeting immuno-inflammatory pathways may in the future represent an attractive therapeutic approach in a number of LQTS patients, thus opening new exciting avenues in antiarrhythmic therapy.
Collapse
Affiliation(s)
- Pietro Enea Lazzerini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena , Siena , Italy
| | - Pier Leopoldo Capecchi
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena , Siena , Italy
| | - Franco Laghi-Pasini
- Department of Medical Sciences, Surgery and Neurosciences, University of Siena , Siena , Italy
| |
Collapse
|
20
|
Monfredi O, Boyett MR. Sick sinus syndrome and atrial fibrillation in older persons - A view from the sinoatrial nodal myocyte. J Mol Cell Cardiol 2015; 83:88-100. [PMID: 25668431 DOI: 10.1016/j.yjmcc.2015.02.003] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Revised: 01/30/2015] [Accepted: 02/02/2015] [Indexed: 01/02/2023]
Abstract
Sick sinus syndrome remains a highly relevant clinical entity, being responsible for the implantation of the majority of electronic pacemakers worldwide. It is an infinitely more complex disease than it was believed when first described in the mid part of the 20th century. It not only involves the innate leading pacemaker region of the heart, the sinoatrial node, but also the atrial myocardium, predisposing to atrial tachydysrhythmias. It remains controversial as to whether the dysfunction of the sinoatrial node directly causes the dysfunction of the atrial myocardium, or vice versa, or indeed whether these two aspects of the condition arise through some related underlying pathological mechanism, such as extracellular matrix remodeling, i.e., fibrosis. This review aims to shed new light on the myriad possible contributing factors in the development of sick sinus syndrome, with a particular focus on the sinoatrial nodal myocyte. This article is part of a Special Issue entitled CV Aging.
Collapse
Affiliation(s)
- O Monfredi
- Institute of Cardiovascular Sciences, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK.
| | - M R Boyett
- Institute of Cardiovascular Sciences, University of Manchester, 46 Grafton Street, Manchester M13 9NT, UK
| |
Collapse
|
21
|
Sedmera D, Kockova R, Vostarek F, Raddatz E. Arrhythmias in the developing heart. Acta Physiol (Oxf) 2015; 213:303-20. [PMID: 25363044 DOI: 10.1111/apha.12418] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Revised: 09/08/2014] [Accepted: 10/23/2014] [Indexed: 01/10/2023]
Abstract
Prevalence of cardiac arrhythmias increases gradually with age; however, specific rhythm disturbances can appear even prior to birth and markedly affect foetal development. Relatively little is known about these disorders, chiefly because of their relative rarity and difficulty in diagnosis. In this review, we cover the most common forms found in human pathology, specifically congenital heart block, pre-excitation, extrasystoles and long QT syndrome. In addition, we cover pertinent literature data from prenatal animal models, providing a glimpse into pathogenesis of arrhythmias and possible strategies for treatment.
Collapse
Affiliation(s)
- D. Sedmera
- Institute of Anatomy; First Faculty of Medicine; Charles University; Prague Czech Republic
- Institute of Physiology; Academy of Sciences of the Czech Republic; Prague Czech Republic
| | - R. Kockova
- Institute of Physiology; Academy of Sciences of the Czech Republic; Prague Czech Republic
- Department of Cardiology; Institute of Clinical and Experimental Medicine; Prague Czech Republic
| | - F. Vostarek
- Institute of Physiology; Academy of Sciences of the Czech Republic; Prague Czech Republic
| | - E. Raddatz
- Department of Physiology; Faculty of Biology and Medicine; University of Lausanne; Lausanne Switzerland
| |
Collapse
|
22
|
Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension. J Hypertens 2014; 32:1898-904. [DOI: 10.1097/hjh.0000000000000270] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Shiraishi I, Nishimura K, Sakaguchi H, Abe T, Kitano M, Kurosaki K, Kato H, Nakanishi T, Yamagishi H, Sagawa K, Ikeda Y, Morisaki T, Hoashi T, Kagisaki K, Ichikawa H. Acute rupture of chordae tendineae of the mitral valve in infants: a nationwide survey in Japan exploring a new syndrome. Circulation 2014; 130:1053-61. [PMID: 25062691 DOI: 10.1161/circulationaha.114.008592] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Recently, infant cases of acute heart failure attributable to rupture of the mitral chordae tendineae have been reported. However, little is known about the pathogenesis and clinical course of this condition. METHODS AND RESULTS Ninety-five children with rupture of mitral chordae tendineae were identified in nationwide surveys of Japan diagnosed from 1995 to 2013. The clinical manifestations, management strategies, and prognosis were investigated. Eighty-one (85%) patients were between 4 and 6 months (median, 5 months) of age. In 63 (66%) patients, rupture occurred during the spring or summer. The underlying conditions before rupture included Kawasaki disease (10 cases), maternally derived anti-SSA antibodies (2 cases), and infective endocarditis (1 case). Surgery was performed in 80 patients (94 operations), and the final operations included plasty of mitral chordae in 52 cases and mechanical valve replacement in 26 cases. The histopathologic examinations of the mitral valves and chordae (n=28) revealed inflammatory reactions with predominant mononuclear cell infiltration in 18 cases (64%) and increased fibrous and myxoid tissue in 11 cases (39%), suggesting that nonbacterial infectious or autoimmune endocarditis and myxoid changes are involved in the pathogenesis. Eight patients (8.4%) died before (n=6) and shortly after (n=2) the operation, and significant neurological complications persisted in 10 cases (11%). CONCLUSIONS Acute heart failure attributable to rupture of the mitral chordae tendineae in infants is a unique disease resulting from diverse causes. This condition should be recognized as a significant cardiovascular disorder that may cause sudden onset of cardiogenic shock and death in infants.
Collapse
Affiliation(s)
- Isao Shiraishi
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.).
| | - Kunihiro Nishimura
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Heima Sakaguchi
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Tadaaki Abe
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Masataka Kitano
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Kenichi Kurosaki
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Hitoshi Kato
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Toshio Nakanishi
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Hiroyuki Yamagishi
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Koichi Sagawa
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Yoshihiko Ikeda
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Takayuki Morisaki
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Takaya Hoashi
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Koji Kagisaki
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| | - Hajime Ichikawa
- From the Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (I.S., H.S., T.A., M.K., K. Kurosaki); the Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Osaka, Japan (K.N.); the Department of Cardiology, National Center for Child Health and Development, Tokyo, Japan (H.K.); the Department of Pediatric Cardiology, Tokyo Women's Medical University, Tokyo, Japan (T.N.); the Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan (H.Y.); the Department of Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan (K.S.); the Department of Clinical Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.I.); the Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Osaka, Japan (T.M.); and the Department of Pediatric Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan (T.H., K. Kagisaki, H.I.)
| |
Collapse
|
24
|
Pervolaraki E, Hodgson S, Holden AV, Benson AP. Towards computational modelling of the human foetal electrocardiogram: normal sinus rhythm and congenital heart block. Europace 2014; 16:758-65. [PMID: 24798966 DOI: 10.1093/europace/eut377] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS We aim to engineer a computational model of propagation during normal sinus rhythm in the foetal human heart, by modifying models for adult cardiac tissue to match foetal electrocardiogram (fECG) characteristics. The model will be partially validated by fECG data, and applied to explore possible mechanisms of arrhythmogenesis in the foetal heart. METHODS AND RESULTS Foetal electrocardiograms have been recorded during pregnancy, with P- and T-waves, and the QRS complex, identified by averaging and signal processing. Intervals of the fECG are extracted and used to modify currently available human adult cardiomyocyte models. RR intervals inform models of the pacemaking cells by constraining their rate, the QT interval and its rate dependence constrain models of ventricular cells, and the width of the P-wave, the QR and PR intervals constrain propagation times, conduction velocities, and intercellular coupling. These cell models are coupled into a one-dimensional (1D) model of propagation during normal sinus rhythm in the human foetal heart. We constructed a modular, heterogeneous 1D model for propagation in the foetal heart, and predicted the effects of reduction in L-type Ca(++) current. These include bradycardia and atrioventricular conduction blocks. These may account quantitatively for congenital heart block produced by positive IgG antibodies. CONCLUSION The fECG can be interpreted mechanistically and quantitatively by using a simple computational model for propagation. After further validation, by clinical recordings of the fECG and the electrophysiological experiments on foetal cardiac cells and tissues, the model may be used to predict the effects of maternally administered pharmaceuticals on the fECG.
Collapse
|
25
|
T-type channels in the sino-atrial and atrioventricular pacemaker mechanism. Pflugers Arch 2014; 466:791-9. [DOI: 10.1007/s00424-014-1482-6] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 02/11/2014] [Accepted: 02/12/2014] [Indexed: 11/26/2022]
|
26
|
Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res 2014; 325:2-9. [PMID: 24434353 DOI: 10.1016/j.yexcr.2014.01.003] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2013] [Revised: 01/02/2014] [Accepted: 01/06/2014] [Indexed: 01/30/2023]
Abstract
Autoantibody-associated congenital heart block (CHB) is a passively acquired autoimmune condition associated with maternal anti-Ro/SSA antibodies and primarily affecting electric signal conduction at the atrioventricular node in the fetal heart. CHB occurs in 1-2% of anti-Ro/SSA antibody-positive pregancies and has a recurrence rate of 12-20% in a subsequent pregnancy. Despite the long-recognized association between maternal anti-Ro/SSA autoantibodies and CHB, the molecular mechanisms underlying CHB pathogenesis are not fully understood, but several targets for the maternal autoantibodies in the fetal heart have been suggested. Recent studies also indicate that fetal susceptibility genes determine whether an autoantibody-exposed fetus will develop CHB or not, and begin to identify such genes. In this article, we review the different lines of investigation undertaken to elucidate the molecular pathways involved in CHB development and reflect on the hypotheses put forward to explain CHB pathogenesis as well as on the questions left unanswered and that should guide future studies.
Collapse
Affiliation(s)
- Aurélie Ambrosi
- Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
| | - Sven-Erik Sonesson
- Department of Women and Child Health, Karolinska Institutet, 171 76 Stockholm, Sweden.
| | - Marie Wahren-Herlenius
- Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
| |
Collapse
|
27
|
Strandberg LS, Cui X, Rath A, Liu J, Silverman ED, Liu X, Siragam V, Ackerley C, Su BB, Yan JY, Capecchi M, Biavati L, Accorroni A, Yuen W, Quattrone F, Lung K, Jaeggi ET, Backx PH, Deber CM, Hamilton RM. Congenital heart block maternal sera autoantibodies target an extracellular epitope on the α1G T-type calcium channel in human fetal hearts. PLoS One 2013; 8:e72668. [PMID: 24039792 PMCID: PMC3767782 DOI: 10.1371/journal.pone.0072668] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2012] [Accepted: 07/17/2013] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Congenital heart block (CHB) is a transplacentally acquired autoimmune disease associated with anti-Ro/SSA and anti-La/SSB maternal autoantibodies and is characterized primarily by atrioventricular (AV) block of the fetal heart. This study aims to investigate whether the T-type calcium channel subunit α1G may be a fetal target of maternal sera autoantibodies in CHB. METHODOLOGY/PRINCIPAL FINDINGS We demonstrate differential mRNA expression of the T-type calcium channel CACNA1G (α1G gene) in the AV junction of human fetal hearts compared to the apex (18-22.6 weeks gestation). Using human fetal hearts (20-22 wks gestation), our immunoprecipitation (IP), Western blot analysis and immunofluorescence (IF) staining results, taken together, demonstrate accessibility of the α1G epitope on the surfaces of cardiomyocytes as well as reactivity of maternal serum from CHB affected pregnancies to the α1G protein. By ELISA we demonstrated maternal sera reactivity to α1G was significantly higher in CHB maternal sera compared to controls, and reactivity was epitope mapped to a peptide designated as p305 (corresponding to aa305-319 of the extracellular loop linking transmembrane segments S5-S6 in α1G repeat I). Maternal sera from CHB affected pregnancies also reacted more weakly to the homologous region (7/15 amino acids conserved) of the α1H channel. Electrophysiology experiments with single-cell patch-clamp also demonstrated effects of CHB maternal sera on T-type current in mouse sinoatrial node (SAN) cells. CONCLUSIONS/SIGNIFICANCE Taken together, these results indicate that CHB maternal sera antibodies readily target an extracellular epitope of α1G T-type calcium channels in human fetal cardiomyocytes. CHB maternal sera also show reactivity for α1H suggesting that autoantibodies can target multiple fetal targets.
Collapse
Affiliation(s)
- Linn S. Strandberg
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Xuezhi Cui
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Arianna Rath
- Division of Molecular Structure and Function, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Jie Liu
- Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Earl D. Silverman
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Xiaoru Liu
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Vinayakumar Siragam
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Cameron Ackerley
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Brenda Bin Su
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Jane Yuqing Yan
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | | | | | | | - William Yuen
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | | | - Kalvin Lung
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Edgar T. Jaeggi
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Peter H. Backx
- Departments of Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada
- Division of Cardiology, University Health Network, Toronto, Ontario, Canada
| | - Charles M. Deber
- Division of Molecular Structure and Function, The Hospital for Sick Children, Toronto, Ontario, Canada
- Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada
| | - Robert M. Hamilton
- Department of Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada
- * E-mail:
| |
Collapse
|
28
|
Karnabi E, Qu Y, Yue Y, Boutjdir M. Calreticulin negatively regulates the surface expression of Cav1.3 L-type calcium channel. Biochem Biophys Res Commun 2013; 437:497-501. [PMID: 23791743 DOI: 10.1016/j.bbrc.2013.06.023] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2013] [Accepted: 06/08/2013] [Indexed: 12/19/2022]
Abstract
BACKGROUND The neuroendocrine Cav1.3 L-type Ca channels have been recently found in the Human fetal heart and shown to play a vital role in Ca entry from the sarcolemma into the cell and in Ca homeostasis. Calreticulin, a Ca binding endoplasmic reticulum (ER) resident protein, has been recently shown to translocate to the cell surface where its role and function are just emerging. Here, we demonstrated a novel mechanism of Cav1.3 and calreticulin interaction resulting in downregulation of Cav1.3 channel densities in native Human fetal cardiac cells and Human Embryonic Kidney cell lines (tsA201). METHODS AND RESULTS Cell surface and cytoplasmic staining of calreticulin was demonstrated first in cultured human fetal cardiomyocytes (HFC), gestational age 18-24 weeks, using confocal microscopy thereby establishing that calreticulin is present at the cell surface in HFC. Co-immunoprecipitation from HFC using anti-Cav1.3 Ca channel antibody, and probing with anti-calreticulin antibody revealed a 46 kDa band corresponding to calreticulin suggesting that Cav1.3 Ca channel and calreticulin co-assemble in a macromolecular complex. Co-expression of Cav1.3 and calreticulin in tsA201 cells resulted in a decrease in surface expression of Cav1.3 Ca channels. These findings were consistent with the electrophysiological studies showing that co-transfection of Cav1.3 Ca channel and calreticulin resulted in 55% reduction of Cav1.3 Ca current densities recorded from tsA201 cells. CONCLUSIONS The results show the first evidence that calreticulin: (1) is localized outside the ER on the cell surface of HFC; (2) coimmunoprecipitates with Cav1.3 L-type Ca channel; (3) negatively regulates Cav1.3 surface expression thus resulting in decreased Cav1.3 Ca current densities. The data demonstrate a novel mechanism of modulation of Cav1.3 Ca channel by calreticulin, which may be involved in pathological settings such as autoimmune associated congenital heart block where Cav1.3 Ca channels are downregulated.
Collapse
Affiliation(s)
- Eddy Karnabi
- Cardiovascular Research Program, Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, Brooklyn, USA
| | | | | | | |
Collapse
|
29
|
Atrioventricular conduction delay in fetuses exposed to anti-SSA/Ro and anti-SSB/La antibodies: a magnetocardiography study. Clin Dev Immunol 2012; 2012:432176. [PMID: 23320018 PMCID: PMC3539448 DOI: 10.1155/2012/432176] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2012] [Revised: 11/27/2012] [Accepted: 11/27/2012] [Indexed: 12/23/2022]
Abstract
Background. The presence of anti-SSA/Ro and anti-SSB/La antibodies during pregnancy is associated with fetal congenital heart block (CHB), which is primarily diagnosed through fetal echocardiography. Conclusive information about the complete electrophysiology of the fetal cardiac conducting system is still lacking. In addition to echocardiography, fetal magnetocardiography (fMCG) can be used. fMCG is the magnetic analogue of the fetal electrocardiogram (ECG). Patients and Methods. Forty-eight pregnant women were enrolled in an observational study; 16 of them tested positive for anti-SSA/Ro and anti-SSB/La antibodies. In addition to routine fetal echocardiography, fMCG was used. Fetal cardiac time intervals (fCTIs) were extracted from the magnetic recordings by predefined procedures. ECGs in the neonates of the study group were performed within the first month after delivery. Results. The PQ segment of the fCTI was significantly prolonged in the study group (P = 0.007), representing a delay of the electrical impulse in the atrioventricular (AV) node. Other fCTIs were within normal range. None of the anti-SSA/Ro and/or anti-SSB/La fetuses progressed to a more advanced heart block during pregnancy or after birth. Conclusion. The study identified a low-risk population within antibody positive mothers, where PQ segment prolongation is associated with a lack of progression of the disease.
Collapse
|
30
|
Kaese S, Verheule S. Cardiac electrophysiology in mice: a matter of size. Front Physiol 2012; 3:345. [PMID: 22973235 PMCID: PMC3433738 DOI: 10.3389/fphys.2012.00345] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Accepted: 08/09/2012] [Indexed: 12/27/2022] Open
Abstract
Over the last decade, mouse models have become a popular instrument for studying cardiac arrhythmias. This review assesses in which respects a mouse heart is a miniature human heart, a suitable model for studying mechanisms of cardiac arrhythmias in humans and in which respects human and murine hearts differ. Section I considers the issue of scaling of mammalian cardiac (electro) physiology to body mass. Then, we summarize differences between mice and humans in cardiac activation (section II) and the currents underlying the action potential in the murine working myocardium (section III). Changes in cardiac electrophysiology in mouse models of heart disease are briefly outlined in section IV, while section V discusses technical considerations pertaining to recording cardiac electrical activity in mice. Finally, section VI offers general considerations on the influence of cardiac size on the mechanisms of tachy-arrhythmias.
Collapse
Affiliation(s)
- Sven Kaese
- Division of Experimental and Clinical Electrophysiology, Department of Cardiology and Angiology, University Hospital Münster Münster, Germany
| | | |
Collapse
|
31
|
Ambrosi A, Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther 2012; 14:208. [PMID: 22546326 PMCID: PMC3446439 DOI: 10.1186/ar3787] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
During pregnancy in autoimmune conditions, maternal autoantibodies are transported across the placenta and may affect the developing fetus. Congenital heart block (CHB) is known to associate with the presence of anti-Ro/SSA and anti-La/SSB antibodies in the mother and is characterized by a block in signal conduction at the atrioventricular (AV) node. The mortality rate of affected infants is 15% to 30%, and most live-born children require lifelong pacemaker implantation. Despite a well-recognized association with maternal anti-Ro/La antibodies, CHB develops in only 1% to 2% of anti-Ro-positive pregnancies, indicating that other factors are important for establishment of the block. The molecular mechanisms leading to complete AV block are still unclear, and the existing hypotheses fail to explain all aspects of CHB in one comprehensive model. In this review, we discuss the different specificities of maternal autoantibodies that have been implicated in CHB as well as the molecular mechanisms that have been suggested to operate, focusing on the evidence supporting a direct pathogenic role of maternal antibodies. Autoantibodies targeting the 52-kDa component of the Ro antigen remain the antibodies most closely associated with CHB. In vitro experiments and animal models of CHB also point to a major role for anti-Ro52 antibodies in CHB pathogenesis and suggest that these antibodies may directly affect calcium regulation in the fetal heart, leading to disturbances in signal conduction or electrogenesis or both. In addition, maternal antibody deposits are found in the heart of fetuses dying of CHB and are thought to contribute to an inflammatory reaction that eventually induces fibrosis and calcification of the AV node, leading to a complete block. Considering that CHB has a recurrence rate of 12% to 20% despite persisting maternal autoantibodies, it has long been clear that maternal autoantibodies are not sufficient for the establishment of a complete CHB, and efforts have been made to identify additional risk factors for this disorder. Therefore, recent studies looking at the influence of genetic and environmental factors will also be discussed.
Collapse
Affiliation(s)
- Aurélie Ambrosi
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden
| | | |
Collapse
|
32
|
Llanos C, Friedman DM, Saxena A, Izmirly PM, Tseng CE, Dische R, Abellar RG, Halushka M, Clancy RM, Buyon JP. Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. Rheumatology (Oxford) 2012; 51:1086-92. [PMID: 22308531 DOI: 10.1093/rheumatology/ker515] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE The autopsy and clinical information on children dying with anti-SSA/Ro-associated cardiac manifestations of neonatal lupus (cardiac NL) were examined to identify patterns of disease, gain insight into pathogenesis and enhance the search for biomarkers and preventive therapies. METHODS A retrospective analysis evaluating reports from 18 autopsies of cardiac NL cases and clinical data from the Research Registry for Neonatal Lupus was performed. RESULTS Of the 18 cases with autopsies, 15 had advanced heart block, including 3 who died in the second trimester, 9 in the third trimester and 3 post-natally. Three others died of cardiomyopathy without advanced block, including two dying pre-natally and one after birth. Pathological findings included fibrosis/calcification of the atrioventricular (AV) node, sinoatrial (SA) node and bundle of His, endocardial fibroelastosis (EFE), papillary muscle fibrosis, valvular disease, calcification of the atrial septum and mononuclear pancarditis. There was no association of pathology with the timing of death except that in the third-trimester deaths more valvular disease and/or extensive conduction system abnormalities were observed. Clinical rhythm did not always correlate with pathology of the conduction system, and the pre-mortem echocardiograms did not consistently detect the extent of pathology. CONCLUSION Fibrosis of the AV node/distal conduction system is the most characteristic histopathological finding. Fibrosis of the SA node and bundle of His, EFE and valve damage are also part of the anti-Ro spectrum of injury. Discordance between echocardiograms and pathology findings should prompt the search for more sensitive methods to accurately study the phenotype of antibody damage.
Collapse
Affiliation(s)
- Carolina Llanos
- Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Chockalingam P, Jaeggi ET, Rammeloo LA, Haak MC, Adama van Scheltema PN, Breur JMPJ, Bartelings MM, Clur SAB, Blom NA. Persistent fetal sinus bradycardia associated with maternal anti-SSA/Ro and anti-SSB/La antibodies. J Rheumatol 2011; 38:2682-5. [PMID: 22089457 DOI: 10.3899/jrheum.110720] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
OBJECTIVE To study the clinical course and outcome of fetal sinus bradycardia (SB) due to maternal antibody-induced sinus node dysfunction. METHODS We reviewed the maternal, prenatal, and postnatal findings of fetuses with SB associated with elevated maternal anti-SSA/Ro and anti-SSB/La antibodies. RESULTS Of the 6 cases diagnosed prenatally, 3 had isolated SB persisting after birth and had a good prognosis. Three fetuses with SB and severe myocardial involvement (congenital complete heart block and/or endocardial fibroelastosis) succumbed in utero in spite of treatment. Postmortem histopathology in 1 fetus showed inflammatory destruction of the sinus and atrioventricular nodes. SB was detected incidentally in a 7-year-old girl. She had intermittent heart block with progressive sinus arrest requiring permanent pacemaker. CONCLUSION Fetal SB associated with maternal autoantibodies may persist in childhood, with a good prognosis in the absence of widespread cardiac involvement.
Collapse
Affiliation(s)
- Priya Chockalingam
- Department of Pediatric Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
|
35
|
Karnabi E, Qu Y, Mancarella S, Boutjdir M. Rescue and worsening of congenital heart block-associated electrocardiographic abnormalities in two transgenic mice. J Cardiovasc Electrophysiol 2011; 22:922-30. [PMID: 21352396 PMCID: PMC3135711 DOI: 10.1111/j.1540-8167.2011.02032.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Congenital heart block (CHB) is a passively acquired autoimmune disease considered to be due to the transfer of maternal autoantibodies, anti-SSA/Ro -SSB/La, to the fetus resulting in atrioventricular (AV) block and sinus bradycardia. We previously established a murine model for CHB where pups born to immunized wild-type (WT) mothers exhibited electrocardiographic abnormalities similar to those seen in CHB and demonstrated inhibition of L-type Ca channels (LTCCs) by maternal antibodies. Here, we hypothesize that overexpression of LTCC should rescue, whereas knockout of LTCC should worsen the electrocardiographic abnormalities in mice. METHODS AND RESULTS Transgenic (TG) mice were immunized with SSA/Ro and SSB/La antigens. Pups born to immunized WT mothers had significantly greater sinus bradycardia and AV block compared to pups from nonimmunized WT. TG pups overexpressing LTCC had significantly less sinus bradycardia and AV block compared to their non-TG littermates and to pups born to immunized WT mothers. All LTCC knockout pups born to immunized mothers had sinus bradycardia, advanced degree of AV block, and decreased fetal parity. No sinus bradycardia or AV block were manifested in pups from control nonimmunized WT mothers. IgG from mothers with CHB children, but not normal IgG, completely inhibited intracellular Ca transient ([Ca](i)T) amplitude. CONCLUSIONS Cardiac-specific overexpression of LTCC significantly reduced the incidence of AV block and sinus bradycardia in pups exposed to anti-SSA/Ro -SSB/La autoantibodies, whereas exposure of LTCC knockout pups to these autoantibodies significantly worsened the electrocardiographic abnormalities. These findings support the hypothesis that maternal antibodies inhibit LTCC and [Ca](i)T thus contributing to the development of CHB. Altogether, the results are relevant to the development of novel therapies for CHB.
Collapse
Affiliation(s)
- Eddy Karnabi
- VA New York Harbor Healthcare System, Brooklyn, NY
- State University of New York Downstate Medical Center, Brooklyn, NY
- Hospital of St. Raphael, New Haven, CT
| | - Yongxia Qu
- VA New York Harbor Healthcare System, Brooklyn, NY
- State University of New York Downstate Medical Center, Brooklyn, NY
| | | | - Mohamed Boutjdir
- VA New York Harbor Healthcare System, Brooklyn, NY
- State University of New York Downstate Medical Center, Brooklyn, NY
- New York University School of Medicine, New York, New York
| |
Collapse
|
36
|
Rose RA, Sellan M, Simpson JA, Izaddoustdar F, Cifelli C, Panama BK, Davis M, Zhao D, Markhani M, Murphy GG, Striessnig J, Liu PP, Heximer SP, Backx PH. Iron overload decreases CaV1.3-dependent L-type Ca2+ currents leading to bradycardia, altered electrical conduction, and atrial fibrillation. Circ Arrhythm Electrophysiol 2011; 4:733-42. [PMID: 21747058 DOI: 10.1161/circep.110.960401] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
BACKGROUND Chronic iron overload (CIO) is associated with blood disorders such as thalassemias and hemochromatosis. A major prognostic indicator of survival in patients with CIO is iron-mediated cardiomyopathy characterized by contractile dysfunction and electrical disturbances, including slow heart rate (bradycardia) and heart block. METHODS AND RESULTS We used a mouse model of CIO to investigate the effects of iron on sinoatrial node (SAN) function. As in humans, CIO reduced heart rate (≈20%) in conscious mice as well as in anesthetized mice with autonomic nervous system blockade and in isolated Langendorff-perfused mouse hearts, suggesting that bradycardia originates from altered intrinsic SAN pacemaker function. Indeed, spontaneous action potential frequencies in SAN myocytes with CIO were reduced in association with decreased L-type Ca(2+) current (I(Ca,L)) densities and positive (rightward) voltage shifts in I(Ca,L) activation. Pacemaker current (I(f)) was not affected by CIO. Because I(Ca,L) in SAN myocytes (as well as in atrial and conducting system myocytes) activates at relatively negative potentials due to the presence of Ca(V)1.3 channels (in addition to Ca(V)1.2 channels), our data suggest that elevated iron preferentially suppresses Ca(V)1.3 channel function. Consistent with this suggestion, CIO reduced Ca(V)1.3 mRNA levels by ≈40% in atrial tissue (containing SAN) and did not lower heart rate in Ca(V)1.3 knockout mice. CIO also induced PR-interval prolongation, heart block, and atrial fibrillation, conditions also seen in Ca(V)1.3 knockout mice. CONCLUSIONS Our results demonstrate that CIO selectively reduces Ca(V)1.3-mediated I(Ca,L), leading to bradycardia, slowing of electrical conduction, and atrial fibrillation as seen in patients with iron overload.
Collapse
Affiliation(s)
- Robert A Rose
- Department of Physiology, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Napolitano C, Antzelevitch C. Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel. Circ Res 2011; 108:607-18. [PMID: 21372292 DOI: 10.1161/circresaha.110.224279] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The L-type cardiac calcium channel (LTCC) plays a prominent role in the electric and mechanical function of the heart. Mutations in the LTCC have been associated with a number of inherited cardiac arrhythmia syndromes, including Timothy, Brugada, and early repolarization syndromes. Elucidation of the genetic defects associated with these syndromes has led to a better understanding of molecular and cellular mechanisms and the development of novel therapeutic approaches to dealing with the arrhythmic manifestations. This review provides an overview of the molecular structure and function of the LTCC, the genetic defects in these channels known to contribute to inherited disorders, and the underlying molecular and cellular mechanisms contributing to the development of life-threatening arrhythmias.
Collapse
Affiliation(s)
- Carlo Napolitano
- Executive Director and Director of Research, Gordon K. Moe Scholar, Masonic Medical Research Laboratory, 2150 Bleecker St, Utica, NY 13501, USA.
| | | |
Collapse
|
38
|
Qu Y, Karnabi E, Ramadan O, Yue Y, Chahine M, Boutjdir M. Perinatal and postnatal expression of Cav1.3 α1D Ca²⁺ channel in the rat heart. Pediatr Res 2011; 69:479-84. [PMID: 21378599 PMCID: PMC3094857 DOI: 10.1203/pdr.0b013e318217a0df] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The novel Cav1.3 (α1D) L-type Ca²⁺ channel plays a significant role in sinoatrial (SA) and atrioventricular (AV) nodes function and in atrial fibrillation. However, the characterization of α1D Ca²⁺ channel during heart development is very limited. We used real-time RT-PCR, Western blotting, and indirect immunostaining to characterize the developmental expression and localization of α1D Ca²⁺ channel in rat hearts. Both protein and mRNA levels of α1D Ca²⁺ channel decreased postnatally. Two forms of α1D Ca²⁺ channel protein (250 and 190 kD) were observed, with the full-length (250 kD) channel protein being predominant in the prenatal stages. Both Western blots and confocal imaging demonstrated that α1D Ca²⁺ channel protein was expressed in both atria and ventricles at fetal and neonatal stages but was absent in the adult ventricles. Interestingly, α1D Ca²⁺ channel was also found at the nucleus/perinucleus of immature but not adult atrial cells. Furthermore, the nuclear staining was reproduced in adult atrial cell line, HL-1 cells, which possess immature properties. The data are first to show that α1D Ca²⁺ channel has unique age-dependent expression profile and subcellular localization in the heart, suggesting a developmental stage-dependent specific function.
Collapse
Affiliation(s)
- Yongxia Qu
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System, Brooklyn, NY 11209, USA
| | | | | | | | | | | |
Collapse
|
39
|
Marger L, Mesirca P, Alig J, Torrente A, Dubel S, Engeland B, Kanani S, Fontanaud P, Striessnig J, Shin HS, Isbrandt D, Ehmke H, Nargeot J, Mangoni ME. Functional roles of Ca(v)1.3, Ca(v)3.1 and HCN channels in automaticity of mouse atrioventricular cells: insights into the atrioventricular pacemaker mechanism. Channels (Austin) 2011; 5:251-61. [PMID: 21406960 DOI: 10.4161/chan.5.3.15266] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The atrioventricular node controls cardiac impulse conduction and generates pacemaker activity in case of failure of the sino-atrial node. Understanding the mechanisms of atrioventricular automaticity is important for managing human pathologies of heart rate and conduction. However, the physiology of atrioventricular automaticity is still poorly understood. We have investigated the role of three key ion channel-mediated pacemaker mechanisms namely, Ca(v)1.3, Ca(v)3.1 and HCN channels in automaticity of atrioventricular node cells (AVNCs). We studied atrioventricular conduction and pacemaking of AVNCs in wild-type mice and mice lacking Ca(v)3.1 (Ca(v)3.1(-/-)), Ca(v)1.3 (Ca(v)1.3(-/-)), channels or both (Ca(v)1.3(-/-)/Ca(v)3.1(-/-)). The role of HCN channels in the modulation of atrioventricular cells pacemaking was studied by conditional expression of dominant-negative HCN4 channels lacking cAMP sensitivity. Inactivation of Ca(v)3.1 channels impaired AVNCs pacemaker activity by favoring sporadic block of automaticity leading to cellular arrhythmia. Furthermore, Ca(v)3.1 channels were critical for AVNCs to reach high pacemaking rates under isoproterenol. Unexpectedly, Ca(v)1.3 channels were required for spontaneous automaticity, because Ca(v)1.3(-/-) and Ca(v)1.3(-/-)/Ca(v)3.1(-/-) AVNCs were completely silent under physiological conditions. Abolition of the cAMP sensitivity of HCN channels reduced automaticity under basal conditions, but maximal rates of AVNCs could be restored to that of control mice by isoproterenol. In conclusion, while Ca(v)1.3 channels are required for automaticity, Ca(v)3.1 channels are important for maximal pacing rates of mouse AVNCs. HCN channels are important for basal AVNCs automaticity but do not appear to be determinant for β-adrenergic regulation.
Collapse
Affiliation(s)
- Laurine Marger
- CNRS, UMR-5203, Institut de Génomique Fonctionnelle, Département de Physiologie, Montpellier, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Greener I, Monfredi O, Inada S, Chandler N, Tellez J, Atkinson A, Taube MA, Billeter R, Anderson R, Efimov I, Molenaar P, Sigg D, Sharma V, Boyett M, Dobrzynski H. Molecular architecture of the human specialised atrioventricular conduction axis. J Mol Cell Cardiol 2011; 50:642-51. [DOI: 10.1016/j.yjmcc.2010.12.017] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2010] [Revised: 12/16/2010] [Accepted: 12/17/2010] [Indexed: 10/18/2022]
|
41
|
Ko ML, Shi L, Grushin K, Nigussie F, Ko GYP. Circadian profiles in the embryonic chick heart: L-type voltage-gated calcium channels and signaling pathways. Chronobiol Int 2011; 27:1673-96. [PMID: 20969517 DOI: 10.3109/07420528.2010.514631] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Circadian clocks exist in the heart tissue and modulate multiple physiological events, from cardiac metabolism to contractile function and expression of circadian oscillator and metabolic-related genes. Ample evidence has demonstrated that there are endogenous circadian oscillators in adult mammalian cardiomyocytes. However, mammalian embryos cannot be entrained independently to light-dark (LD) cycles in vivo without any maternal influence, but circadian genes are well expressed and able to oscillate in embryonic stages. The authors took advantage of using chick embryos that are independent of maternal influences to investigate whether embryonic hearts could be entrained under LD cycles in ovo. The authors found circadian regulation of L-type voltage-gated calcium channels (L-VGCCs), the ion channels responsible for the production of cardiac muscle contraction in embryonic chick hearts. The mRNA levels and protein expression of VGCCα1C and VGCCα1D are under circadian control, and the average L-VGCC current density is significantly larger when cardiomyocytes are recorded during the night than day. The phosphorylation states of several kinases involved in insulin signaling and cardiac metabolism, including extracellular signal-regulated kinase (Erk), stress-activated protein kinase (p38), protein kinase B (Akt), and glycogen synthase kinase-3β (GSK-3β), are also under circadian control. Both Erk and p38 have been implicated in regulating cardiac contractility and in the development of various pathological states, such as cardiac hypertrophy and heart failure. Even though both Erk and phosphoinositide 3-kinase (PI3K)-Akt signaling pathways participate in complex cellular processes regarding physiological or pathological states of cardiomyocytes, the circadian oscillators in the heart regulate these pathways independently, and both pathways contribute to the circadian regulation of L-VGCCs.
Collapse
Affiliation(s)
- Michael L Ko
- Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA
| | | | | | | | | |
Collapse
|
42
|
Abstract
Congenital heart block (CHB) is a conduction abnormality that affects hearts of foetuses and/or newborn to mothers with autoantibodies reactive with the intracellular soluble ribonucleoproteins 48-kD La, 52-kD Ro and 60-kD Ro. CHB carries substantial mortality and morbidity, with more than 60% of affected children requiring lifelong pacemakers. Several hypotheses have been proposed to explain the pathogenesis of CHB. These can be grouped under three main hypotheses: Apoptosis, Serotoninergic and Ca channel hypothesis. Here, we discuss these hypotheses and provide recent scientific thinking that will most likely dominate the future of this field of research.
Collapse
Affiliation(s)
- E Karnabi
- VA New York Harbor Healthcare System, New York, NY, USA
| | | |
Collapse
|
43
|
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses. Scand J Immunol 2010; 72:213-22. [PMID: 20696018 DOI: 10.1111/j.1365-3083.2010.02428.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
It is well established that the passive trans-placental passage of anti-Ro/SSA antibodies from mother to foetus is associated with the risk to develop an uncommon syndrome named neonatal lupus (NLE), where the congenital heart block represents the most severe clinical feature. Recent evidence demonstrated that also adult heart, classically considered invulnerable to the anti-Ro/SSA antibodies, may represent a target of the arrhythmogenicity of these autoantibodies. In particular, the prolongation of the QTc interval appears the most frequent abnormality observed in adults with circulating anti-Ro/SSA antibodies, with some data suggesting an association with an increased risk of ventricular arrhythmias, also life threatening. Moreover, even though the association between anti-Ro/SSA antibodies and conduction disturbances is undoubtedly less evident in adults than in infants, from the accurate dissection of the literature data the possibility arises that sometimes also the adult cardiac conduction tissue may be affected by such antibodies. The exact arrhythmogenic mechanisms involved in foetus/newborns and adults, respectively, have not been completely clarified as yet. However, increasing evidence suggests that anti-Ro/SSA antibodies may trigger rhythm disturbances through an inhibiting cross-reaction with several cardiac ionic channels, particularly the calcium channels (L-type and T-type), but also the potassium channel hERG, whose different expression and involvement in the cardiac electrophysiology during lifespan might account for the occurrence of age-related differences.
Collapse
Affiliation(s)
- P E Lazzerini
- Department of Clinical Medicine and Immunological Sciences, Division of Clinical Immunology, University of Siena, Italy.
| | | | | |
Collapse
|
44
|
Abstract
Congenital heart block is the most severe manifestation of neonatal lupus syndrome. It is a passively acquired disease where transplacental passage of maternal autoantibodies is associated with irreversible damage of the foetal cardiac conduction system. It is well established that the condition, in the absence of structural abnormalities, is strongly associated with maternal autoantibodies to the Ro/La antigens. More specifically the disease has been closely linked to antibodies to the Ro52 component of the antigen complex. Congenital heart block constitutes a unique model where specific autoantibodies target and mediate organ-specific disease. A wide panel of maternal antibodies has been discussed in literature in association with the disease and are described in this review.
Collapse
Affiliation(s)
- S Salomonsson
- Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
| | | |
Collapse
|
45
|
Karnabi E, Qu Y, Wadgaonkar R, Mancarella S, Yue Y, Chahine M, Clancy RM, Buyon JP, Boutjdir M. Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun 2010; 34:80-6. [PMID: 19640679 PMCID: PMC2822065 DOI: 10.1016/j.jaut.2009.06.005] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2009] [Revised: 06/09/2009] [Accepted: 06/14/2009] [Indexed: 11/19/2022]
Abstract
Congenital heart block (CHB) is an autoimmune disease associated with autoantibodies against intracellular ribonucleoproteins SSB/La and SSA/Ro. The hallmark of CHB is complete atrioventricular block. We have recently established that anti-SSA/Ro -SSB/La autoantibodies inhibit alpha(1D) L-type Ca current, I(Ca-L), and cross-react with the alpha(1D) Ca channel protein. This study aims at identifying the possible binding sites on alpha(1D) protein for autoantibodies from sera of mothers with CHB children. GST fusion proteins of the extracellular regions between the transmembrane segments (S5-S6) of each of the four alpha(1D) Ca channel protein domains I-IV were prepared and tested for reactivity with sera from mothers with CHB children and controls using ELISA. Sera containing anti-Ro/La autoantibodies from 118 mothers with CHB children and from 15 mothers with anti-Ro/La autoantibodies but have healthy children, and from 28 healthy mothers without anti-Ro/La autoantibodies and healthy children were evaluated. Seventeen of 118 (14.4%) sera from mothers with CHB children reacted with the extracellular loop of domain I S5-S6 region (E1). In contrast, only 2 of 28 (7%) of sera from healthy mothers (-anti-Ro/La) and healthy children reacted with E1 loop and none (0 of 15) of sera from healthy mothers (+anti-Ro/La) and healthy children reacted with the E1 loop. Preincubation of E1 loop with the positive sera decreased the O.D reading establishing the specificity of the response. Electrophysiological characterization of the ELISA positive sera and purified IgG showed inhibition (44.1% and 49.8%, respectively) of the alpha(1D) I(Ca-L) expressed in tsA201 cells. The inhibition was abolished when the sera were pre-incubated with E1 fusion protein. The results identified the extracellular loop of domain I S5-S6 of L-type Ca channel alpha(1D) subunit as a target for autoantibodies from a subset of mothers with CHB children. This novel finding provides insights into the potential development of therapeutic peptides that could bind to the pathogenic antibodies and prevent CHB.
Collapse
Affiliation(s)
- Eddy Karnabi
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, New York
| | - Yongxia Qu
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, New York
| | - Raj Wadgaonkar
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, New York
| | - Salvatore Mancarella
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, New York
| | - Yuankun Yue
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, New York
| | - Mohamed Chahine
- Le Centre de Recherche Université Laval Robert-Giffard and Department of Medicine, Laval University, Québec, Québec, Canada
| | - Robert M. Clancy
- Department of Medicine, NYU School of Medicine, New York, New York
| | - Jill P. Buyon
- Department of Medicine, NYU School of Medicine, New York, New York
| | - Mohamed Boutjdir
- Molecular and Cellular Cardiology Program, VA New York Harbor Healthcare System and SUNY Downstate Medical Center, Brooklyn, New York
- Department of Medicine, NYU School of Medicine, New York, New York
| |
Collapse
|
46
|
Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: More than expected? Autoimmun Rev 2009; 9:40-4. [DOI: 10.1016/j.autrev.2009.03.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2009] [Accepted: 03/02/2009] [Indexed: 11/18/2022]
|
47
|
Karnabi E, Qu Y, Mancarella S, Yue Y, Wadgaonkar R, Boutjdir M. Silencing of Cav1.2 gene in neonatal cardiomyocytes by lentiviral delivered shRNA. Biochem Biophys Res Commun 2009; 384:409-14. [PMID: 19422800 DOI: 10.1016/j.bbrc.2009.04.150] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2009] [Accepted: 04/10/2009] [Indexed: 11/19/2022]
Abstract
Cav1.2 (alpha1C) and Cav1.3 (alpha1D) L-type Ca channels are co-expressed in the heart. To date, there are no pharmacological or biophysical tools to separate alpha1D from alpha1C Ca currents (I(Ca-L)) in cardiomyocytes. Here, we established a physiological model to study alpha1D I(Ca-L) in native myocytes using RNA interference. Transfection of rat neonatal cardiomyocytes (RNC) with alpha1C specific siRNA resulted in low silencing efficiency (50-60%) at the mRNA and protein levels. The use of lentivirus shRNA resulted in 100% transfection efficiency and 92% silencing of the alpha1C gene by real-time PCR and Western blot. Electrophysiological experiments showed that the total I(Ca-L) was similarly reduced by 80% in lentivirus transfected cells. Both biochemical and functional data demonstrated high transfection and silencing efficiency in the cardiomyocytes using lentiviral shRNA. This novel approach allows for the assessments of the roles of alpha1C and alpha1D Ca channels in native myocytes and could be used to examine their roles in physiological and pathological settings.
Collapse
Affiliation(s)
- Eddy Karnabi
- VA New York Harbor Healthcare System, New York, NY, USA
| | | | | | | | | | | |
Collapse
|
48
|
Liao P, Zhang HY, Soong TW. Alternative splicing of voltage-gated calcium channels: from molecular biology to disease. Pflugers Arch 2009; 458:481-7. [PMID: 19151996 DOI: 10.1007/s00424-009-0635-5] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2008] [Accepted: 01/07/2009] [Indexed: 12/01/2022]
Abstract
Recent developments in the diversification of voltage-gated calcium channel function center on the rapidly emerging role of the posttranscriptional mechanism of alternative splicing. A number of diseases have been found to relate to the dysfunction of alternatively spliced exons arising from either genetic mutations or alterations in the splicing machinery. Mutations in some genes associated with congenital diseases have been detected to reside in alternatively spliced exons. As such, the severity of tissue-selective pathology of the disease will depend on the level of expression of the alternatively spliced exons in that tissue, as well as the extent in the change in channel properties. Importantly, alteration in channel properties is affected by the backbone array of the combinatorial alternatively spliced exons within the channel. In other words, the context by which mutations or alternatively spliced exons are expressed is a great influence on the alteration of channel properties and as such physiology and disease. We reviewed here recent comprehension of alternative splicing of voltage-gated calcium channels and how such structural and functional diversity of voltage-gated calcium channels will aid to clarify the pathophysiology of relevant diseases. Such understandings will further provide guidance for novel treatment.
Collapse
Affiliation(s)
- Ping Liao
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore
| | | | | |
Collapse
|
49
|
Abstract
ABSTRACT
Fetal rhythm abnormalities occur in 2% of pregnancies. They are usually identified by the obstetrician or midwifes after 20 weeks. There are four different methods used to assess fetal arrhythmias: scalp electrodes attached to electrocardiographic recordings, magnetocardiography (FMCG), fetal electrocardiographic recordings from the maternal abdomen, and fetal echocardiography (M-mode, pulsed-Doppler, Tissue-Doppler). In everyday practice the Doppler method was found to be the most useful method in the diagnosis and therapy of fetal arrhythmias. Doppler derived mechanical PR interval raised the possibility of refining the prenatal diagnosis of AV conduction abnormalities. A PR interval of >150 ms on Doppler, FMCG or postnatal ECG has been determined to be prolonged. Extrasystoles are most common cause of fetal arrhythmias, and are most often premature atrial contractions (PACs), what are usually identified in third trimester fetuses and their frequency may be highly variable. These are usually benign, resolving just before or shortly after birth. The follow-up is necessary, because some (1-3%) of affected fetuses have intermittent runs of supraventricular tachycardia. Ventricular tachycardia is rare during fetal life. With echocardiography in the setting of fetal tachycardia the findings of atrioventricular dissociation with a ventricular rate that is faster than the atrial rate suggests ventricular tachycardia. If there is 1:1 retrograde conduction it is impossible to distinguish between ventricular and supraventricular tachycardia. Atrial flutter accounted for 26.2% of all cases of fetal tachyarrhythmias and supraventricular tachycardia for 73.2%. Fouron and coworkers proposed to plan the management of the fetal tachyarrhythmia based on analysis of pulsed-Doppler recordings of fetal heart's blood flow. They determined short V-A tachycardia, when V-A (ventriculoatrial period) was shorter than AV (atrio-ventricular period) period. In the therapy of fetal supraventricular tachycardia there are different protocols, the most commonly used drugs are: digoxin, sotalol, amiodarone, flecainide. Persistent fetal sinus bradycardia is a rare condition and has been reported with central nervous system abnormalities, maternal treatment with beta blockers, excessive vagal tone, hydrops, long QT syndrome, intrauterine growth retardation and could be a sign of maternal anti-SSA/Ro antibodies. Prenatal sinus bradycardia or recognition of 2nd degree AV block may lead to early detection and treatment of long QT syndrome. Early detection of incomplete AV block, in cases of maternal anti SSA, SSB autoantibodies, successfully identifies a group at highest risk developing permanent AV block. The anti-inflammatory effects of dexamethasone might have interrupted on-going damage of the conduction system secondary to maternal autoantibodies. If the fetal arrhythmia resulted fetal hydrops, the mortality is high and the risk of late neurological morbidity must be taken into consideration. As a result of close follow-up, transplacentar treatment and well-organized perinatal management, the survival of sustained fetal arrhythmia significantly improved (50% versus 15%).
Collapse
|
50
|
Ramadan O, Qu Y, Wadgaonkar R, Baroudi G, Karnabi E, Chahine M, Boutjdir M. Phosphorylation of the consensus sites of protein kinase A on alpha1D L-type calcium channel. J Biol Chem 2008; 284:5042-9. [PMID: 19074150 DOI: 10.1074/jbc.m809132200] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The novel alpha(1D) L-type Ca(2+) channel is expressed in supraventricular tissue and has been implicated in the pacemaker activity of the heart and in atrial fibrillation. We recently demonstrated that PKA activation led to increased alpha(1D) Ca(2+) channel activity in tsA201 cells by phosphorylation of the channel protein. Here we sought to identify the phosphorylated PKA consensus sites on the alpha(1) subunit of the alpha(1D) Ca(2+) channel by generating GST fusion proteins of the intracellular loops, N terminus, proximal and distal C termini of the alpha(1) subunit of alpha(1D) Ca(2+) channel. An in vitro PKA kinase assay was performed for the GST fusion proteins, and their phosphorylation was assessed by Western blotting using either anti-PKA substrate or anti-phosphoserine antibodies. Western blotting showed that the N terminus and C terminus were phosphorylated. Serines 1743 and 1816, two PKA consensus sites, were phosphorylated by PKA and identified by mass spectrometry. Site directed mutagenesis and patch clamp studies revealed that serines 1743 and 1816 were major functional PKA consensus sites. Altogether, biochemical and functional data revealed that serines 1743 and 1816 are major functional PKA consensus sites on the alpha(1) subunit of alpha(1D) Ca(2+) channel. These novel findings provide new insights into the autonomic regulation of the alpha(1D) Ca(2+) channel in the heart.
Collapse
Affiliation(s)
- Omar Ramadan
- Veterans Administration, New York Harbor Healthcare System, Brooklyn, New York 11209, USA
| | | | | | | | | | | | | |
Collapse
|